6.4.3. natural history biochemical recurrence. psa recurrence diagnosed, important determine whether recurrence developed local distant sites. sr meta-analysis investigated impact bcr clinical endpoints concluded patients experiencing bcr increased risk developing distant metastases, pca-specific overall mortality . however, effect size bcr risk factor mortality highly variable. primary rp impact ranges hr 1.03 (95% ci: 1.004–1.06) hr 2.32 (95% ci: 1.45–3.71) . primary rt, os rates approximately 20% lower eight ten years follow-up even men minimal co-morbidity . still, variability reported effect sizes bcr remains high suggests certain patient subgroups bcr might increased risk mortality. risk subsequent metastases, pca-specific- overall mortality may predicted initial clinical pathologic factors (e.g., t-category, psa, isup grade group) psa kinetics (psa-dt interval psa failure), investigated sr . patients bcr rp, following outcomes found associated significant prognostic factors: distant metastatic recurrence: positive surgical margins, high rp specimen pathological isup grade group, high pt category, short psa-dt, high pre-srt psa;prostate-cancer-specific mortality: high rp specimen pathological isup grade group, short interval biochemical failure defined investigators, short psa-dt;overall mortality: high rp specimen pathological isup grade group, short interval biochemical failure, high psa-dt. patients bcr rt, corresponding outcomes are: distant metastatic recurrence: high biopsy isup grade group, high ct category, short interval biochemical failure;prostate-cancer-specific mortality: short interval biochemical failure;overall mortality: high age, high biopsy isup grade group, short interval biochemical failure, high initial (pre-treatment) psa. based meta-analysis, proposal stratify patients two risk categories since patients bcr similar outcomes (see table 6.4.1). stratification ‘eau low-risk’ ‘eau high-risk’ bcr rp recently validated european cohort . table 6.4.1: eau risk categories patients developing biochemical recurrence eau low risk bcreau high risk bcrafter rppsa-dt > 1 yrandpathological isup grade group < 4psa-dt ≤ 1 yrorpathological isup grade group 4–5after rtinterval biochemical failure > 18 moandbiopsy isup grade group < 4interval biochemical failure ≤ 18 moorbiopsy isup grade group 4–5